Evidence map›Paper›PMID 40200195›Full record

ArticleBMC cancer2025

Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B.

Jianna Zhang, Zhiqiang Lan, Kailu Zhu, Sijie Yu, Shibo Li, Yu Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jianna ZhangDepartment of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhiqiang LanSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Kailu ZhuDepartment of Infectious Diseases, Taizhou First People's Hospital, Taizhou, China.
Sijie YuDepartment of Infectious Diseases, Zhoushan Hospital Wenzhou Medical University, Zhoushan, China.
Shibo LiDepartment of Infectious Diseases, Zhoushan Hospital Wenzhou Medical University, Zhoushan, China.
Yu HuangDepartment of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. wshuangyu2025@126.com.

Funding

Public Welfare Science and Technology Project of Wenzhou Y2020267Zhejiang Province Major Science and Technology Project for Medicine and Health No.WKJ-ZJ-2329
6 · The paper itself

Abstract

Chronic hepatitis B (CHB) patients who have sustained virological suppression (SVS) still develop hepatocellular carcinoma(HCC), and the risk factors for developing HCC in these patients are not fully understood. This study included a total of 5234 patients who achieved SVS. After SVS, the incidence rate of HCC was 1.9% in 1-8 years and 1.33% in 9-16 years. There was a significant difference between the two periods (P < 0.001). After 1-8 years and 9-16 years of SVS, after multivariate analysis and IPTW adjustment, the factors related to the occurrence of HCC were men, hypertensive patients, diabetes patients and high FIB-4 scores. In summary, patients with CHB who have achieved SVS may still develop HCC. Among them, men, hypertensive patients, diabetes patients and high FIB-4 scores should be listed as the key monitoring objects of HCC. Clinical trial number: Not applicable.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsAdultAgedAntiviral AgentsFemaleHepatitis B virusHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsSustained Virologic ResponseAntiviral AgentsChronic hepatitis B(CHB)Hepatocellular carcinoma(HCC)Risk factorSustained virological suppression (SVS)

Identifiers

PMID40200195
PMCPMC11980259

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.